Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Find generic entry opportunities
Anticipate generic drug launch
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method for administering a sustained release ranolanolazine formulation|
|Abstract:||A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.|
|Inventor(s):||Wolff; Andrew A. (San Francisco, CA), Baker; Fiona (Dunfermline, GB), Langridge; John Richard (Wales, GB)|
|Assignee:||CV Therapeutics, Inc. (Palo Alto, CA)|
1. A method for treating a human patient suffering from variant or exercise-induced angina by administering a sustained release pharmaceutical dosage form including at least 50%
by weight ranolazine and an admixture of at least one pH-dependent binder and at least one pH-independent binder wherein the pharmaceutical dosage form is administered in no more than two tablets per dose to the human patient to maintain ranolazine
plasma levels in the human patient of from about 550 to about 7500 ng base/mL for at least 24 hours wherein the dose is administered at a frequency selected from the group consisting of once, twice or three times over 24 hours and wherein the peak to
trough plasma ranolazine level does not exceed 3:1 over a 24 hour period.
2. The method of claim 1 wherein the sustained release pharmaceutical dosage form consists essentially of an admixture of from about 70 to about 80 wt % ranolazine, from about 5 to about 12.5 wt % methacrylic acid copolymer, from about 1 to about 3 wt % hydroxypropyl methylcellulose, microcrystalline cellulose, sodium hydroxide, and magnesium sterate, wherein each compressed tablet includes from about 350 to about 800 mg ranolazine.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.